Literature DB >> 30527590

MDSC; the Most Important Cell You Have Never Heard Of.

R J Tesi1.   

Abstract

The myeloid-derived suppressor cell (MDSC) is the 'queen bee' of the tumor microenvironment. MDSCs protect the cancer from the patient's immune system, make the tumor resistant to immunotherapy, and allow the tumor to thrive while the patient withers away. Eliminating MDSCs should improve response rates to cancer therapy and patient survival.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer therapy; myeloid-derived suppressor cell; tumor microenvironment

Mesh:

Year:  2018        PMID: 30527590     DOI: 10.1016/j.tips.2018.10.008

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  81 in total

Review 1.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  Active Microneedle Administration of Plant Virus Nanoparticles for Cancer in situ Vaccination Improves Immunotherapeutic Efficacy.

Authors:  Christine E Boone; Chao Wang; Miguel Angel Lopez-Ramirez; Veronique Beiss; Sourabh Shukla; Paul L Chariou; Daniel Kupor; Ricardo Rueda; Joseph Wang; Nicole F Steinmetz
Journal:  ACS Appl Nano Mater       Date:  2020-08-07

3.  Modulating microenvironments for treating glioblastoma.

Authors:  LaDeidra Monet Roberts; Jennifer Munson
Journal:  Curr Tissue Microenviron Rep       Date:  2020-08-13

4.  Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.

Authors:  Fatma Babikr; Jiangbo Wan; Aizhang Xu; Zhaojia Wu; Shahid Ahmed; Andrew Freywald; Rajni Chibbar; Yue Wu; Michael Moser; Gary Groot; Wenjun Zhang; Bing Zhang; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2021-11-15       Impact factor: 11.530

5.  Toll-like Receptor 4 Inhibitor TAK-242 Improves Fulminant Hepatitis by Regulating Accumulation of Myeloid-Derived Suppressor Cell.

Authors:  Haiyan Wang; Xuehui Li; Guanjun Dong; Fenglian Yan; Junfeng Zhang; Hui Shi; Zhaochen Ning; Min Gao; Dalei Cheng; Qun Ma; Changying Wang; Mingsheng Zhao; Jun Dai; Chunxia Li; Zhihua Li; Hui Zhang; Huabao Xiong
Journal:  Inflammation       Date:  2020-10-20       Impact factor: 4.092

6.  Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation.

Authors:  Luca Cassetta; Kirsten Bruderek; Joanna Skrzeczynska-Moncznik; Oktawia Osiecka; Xiaoying Hu; Ida Marie Rundgren; Ang Lin; Kim Santegoets; Utku Horzum; Ana Godinho-Santos; Gennadiy Zelinskyy; Thalia Garcia-Tellez; Sunčica Bjelica; Bartłomiej Taciak; Astrid Olsnes Kittang; Benedikt Höing; Stephan Lang; Michael Dixon; Verena Müller; Jochen Sven Utikal; Derya Karakoç; Kerim Bora Yilmaz; Emilia Górka; Lubomir Bodnar; Olympia Evdoxia Anastasiou; Christine Bourgeois; Robert Badura; Monika Kapinska-Mrowiecka; Mirjana Gotic; Mark Ter Laan; Esther Kers-Rebel; Magdalena Król; Juan Francisco Santibañez; Michaela Müller-Trutwin; Ulf Dittmer; Ana Espada de Sousa; Güneş Esendağlı; Gosse Adema; Karin Loré; Elisabeth Ersvær; Viktor Umansky; Jeffrey W Pollard; Joanna Cichy; Sven Brandau
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

Review 7.  MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.

Authors:  Chi Ma; Qianfei Zhang; Tim F Greten
Journal:  Cell Immunol       Date:  2021-01-21       Impact factor: 4.868

Review 8.  Tumor immune microenvironment in head and neck cancers.

Authors:  Samantha M Y Chen; Alexandra L Krinsky; Rachel A Woolaver; Xiaoguang Wang; Zhangguo Chen; Jing H Wang
Journal:  Mol Carcinog       Date:  2020-02-03       Impact factor: 4.784

9.  Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles.

Authors:  Aixue Li; Yunan Zhao; Yixiu Li; Liangdi Jiang; Yongwei Gu; Jiyong Liu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 10.  Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis.

Authors:  Nerina Denaro; Marco Carlo Merlano; Cristiana Lo Nigro
Journal:  Cancer Manag Res       Date:  2021-05-17       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.